Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses.
Journal Information
Full Title: Ann Hematol
Abbreviation: Ann Hematol
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
1/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
Data Sharing
Code Sharing
COI Disclosure
Funding Disclosure
Evidence found in paper:
"We thank Celgene Corporation for providing lenalidomide for this case series. This work was supported by a grant from the German Bundesministerium für Bildung und Forschung (BMBF), Kompetenznetz “akute und chronische Leukämien.”"
Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025